期刊文献+

治疗用卡介苗抑瘤小鼠模型的建立 被引量:2

Establishment of a mouse model for tumor suppression of therapeutic
原文传递
导出
摘要 目的建立治疗用卡介苗抑瘤小鼠模型,以研究治疗用卡介苗的抗肿瘤疗效。方法分别将适宜浓度的治疗用卡介苗溶液(20、10和5mg/ml)、环磷酰胺溶液(7.2mg/ml)和灭菌生理氯化钠溶液与适宜浓度的小鼠肝癌H22细胞(1×10^7个/ml)混合制成治疗用卡介苗处理液、阳性对照液和阴性对照液,皮下接种BALB/c小鼠,接种后4周,测定小鼠的肿瘤大小和重量,计算每组小鼠的平均肿瘤重量和瘤重抑制率,采用t检验对测定的结果进行统计学分析。结果与阴性对照组相比,10mg/ml治疗用卡介苗处理组的肿瘤重量明显减轻(t=3.41,P〈0.05),肿瘤体积明显缩小(t=4.88,P〈0.05),表明采用治疗用卡介苗处理可使肿瘤生长受到抑制。结论建立的治疗用卡介苗抑瘤小鼠模型可用于卡介苗的抗肿瘤疗效研究。 Objective To establish a mouse model for studying tumor suppression of therapeutic BCG (tBCG). Methods tBCG treatment, positive control and negative control solutions were prepared by mixing tBCG (20, 10 and 5 mg/ml), cyclophosphamide(7.2 mg/ml)and sterile sodium chloride solutions with mouse liver cancer H22 cell solution (1 × 10^7/ml), respectively, and BALB/c mice were inoculated subcutaneously with a kind of mixed preparations. Tumor sizes and weights of mice were measured, and average weights and suppression rates of tumor were calculated. The statistical analysis of the results was made by t tset. Results Tumor weights and sizes in tBCG treatment group( 10 mg/ml) reduced significantly as compared with those in negative group ( t = 3.41, P 〈 0. 05 ; t = 4. 88, P 〈 0. 05 ). The results suggested tBCG treatment could suppress tumor growth. Conclusion The established mouse model for tumor suppression of tBCG can be used for studying antitumor effect of tBCG.
出处 《国际生物制品学杂志》 CAS 2011年第6期289-292,共4页 International Journal of Biologicals
关键词 卡介苗 抗肿瘤药 模型 动物 BCG vaccine Antineoplastic agents Models, animal
  • 相关文献

参考文献6

  • 1Morales A, Eidinger D, Bruce AW. Intracaritary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors [J]. J Urol, 1976, 116(2) :180-183.
  • 2黄建.国内外卡介苗治疗膀胱癌的经验与展望[J].微生物学免疫学进展,2003,31(1):26-30. 被引量:10
  • 3Wang R, Klegeman ME, Marsden I, et al. An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine ) [ J ~.Biochem .1, 1995, 311 (3) :867-872.
  • 4Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall : an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer [ J]. J Urol, 1996, 156(3) :1189-1193.
  • 5Patard J J, Muscatelli-Groux B, Saint F, et al. Evaluation of local immune response after intravesical bacille Calmette-Gu6rin treatment for superficial bladder cancer [ J]. Br J Urol, 1996,78(5) :709-714.
  • 6Bevers RF, de Boer EC, Kurth KH, et al. Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells invitro induced by bacille Calmette-Gu6rin [ J]. Br J Urol, 1997, 80(1) :35-39.

二级参考文献17

共引文献9

同被引文献8

  • 1Ajili F, Kacem M, Tounsi H, et al. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34 [J]. Uhrastruct Pathol, 2012, 36 (5): 336-342.
  • 2Parkin DM. The global burden of urinary bladder cancer [J]. Scand J Urol Nephrol Suppl, 2008 (218): 12-20.
  • 3Crispen R. History of BCG and its substrains [J]. Prog Clin Biol Res, 1989, 310 (1): 35-50.
  • 4Mathe G, Amiel JL, Schwarzenberg L, et al. Active immu- notherapy for acute lymphoblastic leukaemia [J]. Lancet, 1969, 1 (7597): 697-699.
  • 5Zbar B, Bernstein ID, Bartlett GL, et al. Imnmnotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium boris [J]. J Natl Cancer Inst, 1972, 49 (1): 119-130.
  • 6Askeland E J, Newton MR, OJDonnell MA, et al. Bladder cancer immunotherapy: BCG and beyond [J]. Adv Urol, 2012, 2012: 181987-181999.
  • 7王鹏,赵爱华,寇丽杰,乔来艳,李贤珍,岳婷婷,王国治.冻存H_(22)细胞在卡介苗抑瘤小鼠模型中的应用[J].中国生物制品学杂志,2013,26(8):1100-1101. 被引量:2
  • 8晏子厚,何菊,曹慧,杨永芳,徐永革,严东珍,秦若蜀,马昭明,孙卓,荣祖元.治疗用卡介苗抗肿瘤动物实验方法的建立[J].中国生物制品学杂志,2002,15(6):363-365. 被引量:8

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部